Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

By: via Benzinga
Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from the second large clinical validation study of Oncotype DX® in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.